DNA — Ginkgo Bioworks Holdings, Inc.
—
NYSE ·
Health Care ·
Biotechnology ·
CIK 1830214 ·
Last close
$8.32
Market Cap
$448.81M
52W High
$18.22
52W Low
$5.37
ADV30
2,721,209
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | — | — | — | — | — | — | — |
| Jun 2026 | 20,156,000 | 18,437,000 | -58,548,000 | -46,710,000 | 990,046,000 | 84,535,000 | 569,762,000 |
| Mar 2026 | 19,474,000 | 16,376,000 | -71,374,000 | -82,587,000 | 1,033,075,000 | 143,864,000 | 589,922,000 |
| Dec 2025 | 33,396,000 | 26,095,000 | -70,046,000 | -80,751,000 | 1,119,696,000 | 167,202,000 | 611,106,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-164,632,000
Investing CF
$105,217,000
Financing CF
$31,116,000
CapEx
$-6,557,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-4.23
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-6,320,601,000
Inventory
—
Receivables
$11,485,000
ST Investments
$200,857,000
EBIT TTM
$-253,321,000
Pretax Income TTM
$-255,981,000
Interest Exp TTM
—
Analysts
2
Yahoo Snapshot (yfinance, live)
Total Revenue
$130,752,000
EBITDA
$-231,000,992
Free Cash Flow
$-88,832,496
Enterprise Value
$734,729,600
Total Cash
$285,360,992
Total Debt
$397,198,016
Shares Out
53,943,682
Trailing EPS
$-4.24
Book Value
$6.09
ROE
-58.2%
ROA
-15.5%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 170,155,000 | -303,880,000 | -312,763,000 | 1,119,696,000 | 611,106,000 | 508,590,000 | -171,059,000 |
| Dec 2024 | 227,043,000 | -487,727,000 | -547,029,000 | 1,377,449,000 | 661,391,000 | 716,058,000 | -319,585,000 |
| Dec 2023 | 251,455,000 | -768,196,000 | -892,869,000 | 1,665,342,000 | 568,190,000 | 1,097,152,000 | -295,500,000 |
| Dec 2022 | 477,706,000 | -2,208,952,000 | -2,104,929,000 | 2,539,321,000 | 803,044,000 | 1,736,277,000 | -252,198,000 |
TTM Snapshot
Revenues TTM
$111,863,000
NetIncome TTM
$-290,803,000
OpCashFlow TTM
—
Assets (Latest)
$990,046,000
Forward EPS
$-2.90
Max Pain — expiry 2026-12-18
max pain strike: $11.00 · spot: $8.44 · call oi: 41,130 · put oi: 13,937
Expected Move to 2026-12-18:
±$1.90
(22.51%) —
implied range
$6.54 –
$10.34
· ATM straddle on $8.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CADL | Candel Therapeutics, Inc. | $423.61M | $5.40 | — |
| RGNX | REGENXBIO Inc. | $478.73M | $7.24 | — |
| FENC | FENNEC PHARMACEUTICALS INC. | $479.44M | $13.58 | — |
| IRLA | IRulya Therapeutics Inc. | $416.85M | $38.45 | — |
| TECX | Tectonic Therapeutic, Inc. | $392.55M | $20.08 | — |
News headlines (Yahoo Finance, 1h cache)
Ginkgo Bioworks Holdings Inc (DNA) Q3 2026 Earnings Call Highlights: Cost Cuts, First Big ...
2026-11-12 05:05 · Yahoo
Ginkgo Bioworks Q3 Earnings Call Highlights
2026-11-07 08:17 · Yahoo
Ginkgo Bioworks Holdings, Inc. Q3 2026 Earnings Call Summary
2026-11-06 13:30 · Yahoo
Ginkgo Bioworks (DNA) Q3 2026 Earnings Call Transcript
2026-11-06 07:47 · Yahoo
Ginkgo Bioworks Reports Third Quarter 2026 Results; Signs First Autonomous Lab Sale to a Top-Tier Pharma Company Novo
2026-11-05 21:05 · Yahoo
Ginkgo Bioworks Holdings, Inc. (DNA) Suffers a Larger Drop Than the General Market: Key Insights
2026-10-29 21:15 · Yahoo
Ginkgo Bioworks Holdings, Inc. (DNA) Stock Falls Amid Market Uptick: What Investors Need to Know
2026-10-20 21:15 · Yahoo
Ginkgo Bioworks (DNA) Stock Fair Value Edges Higher After Analysts Reassess AI Demand
2026-10-14 23:20 · Yahoo
Here's Why Ginkgo Bioworks Holdings, Inc. (DNA) Fell More Than Broader Market
2026-10-14 21:15 · Yahoo
Araceli Biosciences and Ginkgo Bioworks Bring Cellular Imaging at Scale to Nebula's Lab-in-the-Loop
2026-10-08 10:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.